Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Hopkins Faculty Lead Development of Report to F.D.A. on Ethical, Scientific Issues Related to 'Post-Market' Clinical Trials - 07/12/2010

Hopkins Faculty Lead Development of Report to F.D.A. on Ethical, Scientific Issues Related to 'Post-Market' Clinical Trials

Johns Hopkins Berman Institute of Bioethics plays prominent role
Release Date: July 12, 2010

Amid growing concerns about clinical trials for drugs that have been approved by the F.D.A. but are later linked to serious health risks, an independent committee at the Institute of Medicine led by two professors from Johns Hopkins University has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial “post-market” drug-safety trials.

 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer